N/A N=208 Extending HIV Care Beyond the Rural Health Center
HIV · HIV Infections
Primary: Lost to Follow-up — 5; 5 participants — p=1.0
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=26 Effect of Repetitive Transcranial Magnetic Stimulation on Resting State Brain Activity in Schizophrenia
Schizophrenia
Primary: Changes in Auditory Hallucinations Questionnaire (AHQ). — -2.67; -1.80; -2.50 units on a scale
Phase 3 N=117 Safety and Efficacy of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Chronic Genotype 1 or 3 HCV Infection
Chronic HCV Infection
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12) — 90; 96.4; 100.0; 93.3 percentage of participants
Phase 3 N=38 Recombinant Factor VIIa BI (rFVIIa BI) Treatment of Acute Bleeding Episodes Per an On-demand Regimen
Hemophilia A · Hemophilia B
Primary: Percentage of Bleeding Episode With "Treatment Success" — 96.19; 79.30 percent of bleeding episodes
Phase 2 N=155 Efficacy and Safety of Βeta-adrenoceptor Inverse Agonist and Biased Ligand, Nadolol, In Smoking Cessation of Patients With Chronic Cough With or Without Airflow Obstruction
Smoking Cessation
Primary: Change From Baseline in the Average Number of Cigarettes Smoked Per Day — 36; 45; 36; 28 participants
Phase 4 N=276 Calcichew D3 Preference Study in Participants Eligible for Calcium and Vitamin D Supplementation.
Calcium and Vitamin D Deficiencies
Primary: Percentage of Participants With a Preference for Each Treatment Within Each Test Group — 67.2; 72.3; 61.8; 52.9 percentage of participants
Phase 3 N=516 A Study to Evaluate the Safety and Efficacy of MabThera (Rituximab) in Combination With Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Who Failed on Anti-Tumor Necrosis Factor Alpha Therapy
Rheumatoid Arthritis
Primary: Number of Participants With American College of Rheumatology 20 Response at Week 24 — 36; 153 participants
Phase 3 N=520 Effect of High Dose Ciclesonide on Asthma Control
Bronchial Asthma
Primary: Asthma Control Questionnaire (ACQ) Score at Baseline — 2.24; 2.15; 2.19 units on a scale
Phase 2 N=190 Phase 2, Observer-Blind, Placebo-Controlled, Randomized, Multi-Center Extension Study to Evaluate the Safety and Immunogenicity of a Booster Dose of a MenABCWY Vaccine Administered 24 Months Following the Primary Series to Adolescents and Young Adults Who Participated in V102_03 (NCT01272180)
Meningococcal Disease
Primary: 1. Percentages of Subjects With HT-hSBA (High-throughput Human Serum Bactericidal Assay) Seroresponse Against N. Meningitidis Serogroups A, C, W and Y. — 96; 94; 85; 100…
Phase 4 N=23 Lazanda Fentanyl Nasal Spray Pre Radiofrequency Nerve Ablations(RFA) of Lumbar Facet Joints
Minor Procedural Pain
Primary: Safety and Tolerability as Measured by the Number of Adverse Events — 0 adverse events
Phase 4 N=268 Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors
Primary Brain Tumor
Primary: Percentage of Patients With Overall Lesion Visualization and Characterization Scored as Good or Excellent — 94.0; 96.2; 93.2; 90.6 percentage of patients
Phase 2 N=33 Safety Study of Pyridostigmine in Heart Failure
Heart Failure
Primary: Baseline Heart Rate Recovery — 32.5; 30.4 beats per minute
Phase 3 N=124 A Safety and Efficacy Study of BCD-080 Compared to Clexan for Deep Vein Thrombosis Prophylaxis at Orthopedic Surgeries
Deep Vein Thrombosis
Primary: Frequency of DVT. — 0; 2 participants — p=0.226
Phase 2 N=14 Lexapro for the Treatment of Traumatic Brain Injury (TBI) Depression & Other Psychiatric Conditions
TBI · Major Depression · Other Psychiatric Disorders
Primary: Montgomery-Asberg Depression Rating Scale (MADRS) at Baseline — 29.5; 33.6 units on a scale
Phase 3 N=128 Study of the Efficacy and Safety of Empegfilgrastim for Neutropenia Prophylaxis in Breast Cancer Patients
Chemotherapy-induced Neutropenia
Primary: Duration of Neutropenia CTCAE Grade 4 — 0.905; 0.791; 1.725 days